Vericella™
Vericella™ is saving lives through scalable, minimally invasive tools for the early detection of gastric cancer—powered by AI, designed for global health systems.
“Gastric cancer is the third leading cause of cancer death worldwide, yet the majority of cases are diagnosed too late for effective treatment.”
We dramatically improve survival rates through screening and surveillance by making early detection accessible, affordable, and patient-friendly.
Our core technology was developed by leading researchers at the University of Washington, a global hub for biomedical innovation. This novel diagnostic system enables the collection of stomach lining cells without sedation or full endoscopy. Designed for use in GI clinics and population screening programs, the few minute procedure supports cytological and molecular analysis for early detection of precancerous and cancerous changes. With an accessible cost target per test, Vericella™ is creating a platform built for scale—not scarcity.
-
![]()
Aadil Diwan
Co-Founder & Chief Executive Officer
-
![]()
Eric J. Seibel, Ph.D.
Co-Founder & Chief Scientific Officer
Contact Us
Interested in collaborating? Share your details and a member of our team will be in touch shortly.